Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) Gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection Against...

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2005 Feb 1

PMID 15681415

Citations 18

Authors

Santhi Gorantla

Kathlyn Santos

Vakara Meyer

Stephen Dewhurst

William J Bowers

Howard J Federoff

Howard E Gendelman

Larisa Poluektova

Affiliations

Soon will be listed here.

Abstract

Small-animal models are needed to test human immunodeficiency virus (HIV) vaccine efficacy following viral challenge. To this end, we examined HIV-1-specific immune responses following immunization of nonobese diabetic-severe combined immunodeficient mice that were repopulated with human peripheral blood lymphocytes (hu-PBL-NOD/SCID mice). Autologous dendritic cells (DC) were transduced ex vivo with replication-defective, helper virus-free, herpes simplex virus type 1 (HSV-1) amplicons that expressed HIV-1 gp120 and were then injected into the hu-PBL-NOD/SCID mice. This resulted in primary HIV-1-specific humoral and cellular immune responses. Serum samples from vaccinated animals contained human immunoglobulin G that reacted with HIV-1 Env proteins by enzyme-linked immunosorbent assay and neutralized the infectivity of HIV-1 LAI and ADA strains. T cells isolated from the mice responded to viral antigens by producing gamma interferon when analyzed by enzyme-linked immunospot assay. Importantly, exposure of the vaccinated animals to infectious HIV-1 demonstrated partial protection against infectious HIV-1 challenge. This was reflected by a reduction in HIV-1(ADA) and by protection of the engrafted human CD4(+) T lymphocytes against HIV-1(LAI)-induced cytotoxicity. These data demonstrate that transduction of DC by HSV amplicon vectors expressing HIV-1 gp120 induce virus-specific immune responses in hu-PBL-NOD/SCID mice. This mouse model may be a useful tool to evaluate human immune responses and protection against viral infection following vaccination.

Citing Articles

The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors.

Kamel M, Munds R, Verma M Int J Mol Sci. 2023; 24(22).

PMID: 38003300 PMC: 10671728. DOI: 10.3390/ijms242216112.

Use of Hu-PBL Mice to Study Pathogenesis of Human-Restricted Viruses.

Brunetti J, Kitsera M, Munoz-Fontela C, Rodriguez E Viruses. 2023; 15(1).

PMID: 36680271 PMC: 9866769. DOI: 10.3390/v15010228.

Humanized mice: novel model for studying mechanisms of human immune-based therapies.

Gonzalez L, Strbo N, Podack E Immunol Res. 2013; 57(1-3):326-34.

PMID: 24248605 PMC: 3966553. DOI: 10.1007/s12026-013-8471-2.

Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.

Zhang J, Mulvenon A, Makarov E, Wagoner J, Knibbe J, Kim J Biomaterials. 2013; 34(15):3846-57.

PMID: 23403120 PMC: 3602242. DOI: 10.1016/j.biomaterials.2013.01.026.

Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.

Chentoufi A, Dervillez X, Rubbo P, Kuo T, Zhang X, Nagot N Curr Trends Immunol. 2013; 13:51-68.

PMID: 23355766 PMC: 3552495.

References

Mosier D, Gulizia R, MacIsaac P, Mathieson B, Smith G, Hu S . Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model. AIDS Res Hum Retroviruses. 1992; 8(8):1387. DOI: 10.1089/aid.1992.8.1387. View

Parker K, Tsukui T, Pendleton C, Coligan J, Berzofsky J . Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int Immunol. 1996; 8(5):641-9. DOI: 10.1093/intimm/8.5.641. View

Tanaka T, Tsudo M, Karasuyama H, Kitamura F, Kono T, Hatakeyama M . A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J Immunol. 1991; 147(7):2222-8. View

Schuitemaker H . Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis?. J Leukoc Biol. 1994; 56(3):218-24. DOI: 10.1002/jlb.56.3.218. View

Joag S . Primate models of AIDS. Microbes Infect. 2000; 2(2):223-9. DOI: 10.1016/s1286-4579(00)00266-5. View

Thomsen L, Topley P, Daly M, Brett S, Tite J . Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine. 2004; 22(13-14):1799-809. DOI: 10.1016/j.vaccine.2003.09.052. View

Pollock P, Germolec D, Comment C, Rosenthal G, Luster M . Development of human lymphocyte-engrafted SCID mice as a model for immunotoxicity assessment. Fundam Appl Toxicol. 1994; 22(1):130-8. DOI: 10.1006/faat.1994.1016. View

Chakrabarti B, Kong W, Yang Z, Friborg J, Ling X, King S . Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol. 2002; 76(11):5357-68. PMC: 137015. DOI: 10.1128/jvi.76.11.5357-5368.2002. View

Fais S, Lapenta C, Santini S, Spada M, Parlato S, Logozzi M . Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection. J Virol. 1999; 73(8):6453-9. PMC: 112726. DOI: 10.1128/JVI.73.8.6453-6459.1999. View

10.

Mikloska Z, Bosnjak L, Cunningham A . Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J Virol. 2001; 75(13):5958-64. PMC: 114311. DOI: 10.1128/JVI.75.13.5958-5964.2001. View

11.

Sena-Esteves M, Saeki Y, Fraefel C, Breakefield X . HSV-1 amplicon vectors--simplicity and versatility. Mol Ther. 2000; 2(1):9-15. DOI: 10.1006/mthe.2000.0096. View

12.

Mosier D, Gulizia R, Baird S, Wilson D, Spector D, Spector S . Human immunodeficiency virus infection of human-PBL-SCID mice. Science. 1991; 251(4995):791-4. DOI: 10.1126/science.1990441. View

13.

Lapenta C, Santini S, Logozzi M, Spada M, Andreotti M, Di Pucchio T . Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med. 2003; 198(2):361-7. PMC: 2194078. DOI: 10.1084/jem.20021924. View

14.

Bower J, Yang X, Sodroski J, Ross T . Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol. 2004; 78(9):4710-9. PMC: 387675. DOI: 10.1128/jvi.78.9.4710-4719.2004. View

15.

Gendelman H, Orenstein J, Martin M, Ferrua C, Mitra R, Phipps T . Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med. 1988; 167(4):1428-41. PMC: 2188914. DOI: 10.1084/jem.167.4.1428. View

16.

Warren J . Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates. J Med Primatol. 2002; 31(4-5):237-56. DOI: 10.1034/j.1600-0684.2002.02010.x. View

17.

Hewer R, Meyer D . Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits. Mol Immunol. 2003; 40(6):327-35. DOI: 10.1016/s0161-5890(03)00163-9. View

18.

Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, Kano M . Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med. 2004; 199(12):1709-18. PMC: 2212812. DOI: 10.1084/jem.20040432. View

19.

Banchereau J, Fay J, Pascual V, Palucka A . Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Novartis Found Symp. 2003; 252:226-35. View

20.

Nath B, Schumann K, Boyer J . The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol. 2000; 8(9):426-31. DOI: 10.1016/s0966-842x(00)01816-3. View